Deferiprone-d3 is intended for use as an internal standard for the quantification of deferiprone by GC- or LC-MS. Deferiprone is an iron chelator that binds to iron in a 3:1 (ligand:iron) ratio and has antioxidant and neuroprotective activities.1 It reduces levels of intracellular iron and inhibits lipid peroxidation in primary rat hepatocytes when used at concentrations of 200 and 50 μM, respectively.2 Deferiprone reduces cholesterol diet-induced increases in the levels of amyloid-β (1-42) (Aβ42), Aβ40, and the phosphorylation of tau and glycogen synthase kinase 3β (GSK3β) in the rabbit hippocampus when administered at a dose of 50 mg/kg.3 Formulations containing deferiprone have been used in the treatment of thalassemia.

|1. BarnabÉ, N., Zastre, J.A., Venkataram, S., et al. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic. Biol. Med. 33(2), 266-275 (2002).|2. Morel, I., Cillard, J., Lescoat, G., et al. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: Comparison of their mechanism of protection with that of desferrioxamine. Free Radic. Biol. Med. 13(5), 499-508 (1992).|3. Prasanthi, J.R., Schrag, M., Dasari, B., et al. Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet. J. Alzheimers Dis. 30(1), 167-182 (2012).